Novel Interventions to Reduce Morbidity and Mortality of Hemodialysis Patients – Safety and Other Early Phase Studies

The purpose of this Funding Opportunity Announcement (FOA)  is to initiate and implement a network of participating clinical centers and a data coordinating center to perform pilot and feasibility studies of novel therapies and procedures, including anti-inflammatory therapies, device or procedural interventions, anti-depressive therapies and other psychosocial interventions, and/or combination therapies, in end-stage renal disease (ESRD) patients undergoing chronic maintenance hemodialysis (HD).  Studies will focus on safety; feasibility; identification of dosing, pharmacokinetic, and pharmacodynamic aspects (where appropriate); and identification and preliminary evaluation of potential outcomes.  Applicants are required to propose two studies to be performed sequentially over the funding period. When applicable, clinical site investigators will enlist industry collaboration to achieve the goals of the network. Investigators will also work collaboratively to implement common study protocols developed by the Steering Committee. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trials of therapies or interventions to reduce morbidity and mortality in patients undergoing maintenance hemodialysis.

Application Instructions

As the School of Medicine may only submit 1 proposal for this opportunity, the Office of Research and Graduate Education has established an internal review process to determine which proposal will move forward to the funding agency.

To apply for this funding opportunity, please email a 1-2 page letter of intent describing your proposed aims and approach, a list of all anticipated investigators, and a biosketch of the PI to RGE at rgeopps@uw.edu by Tuesday, October 16, 2012.  Applicants will be notified as soon as a decision is reached.